Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
25-Mar-2025 | 5,087 | 5,090 | 4,938.8 | 5,033.2 | 17,541 | 42,35,92,166.85 | 43,116 |
26-Mar-2025 | 5,029 | 5,080 | 4,966.6 | 5,003.2 | 11,316 | 44,38,52,327.7 | 45,349 |
27-Mar-2025 | 5,003 | 5,003 | 4,905 | 4,960.15 | 17,361 | 63,31,97,253.8 | 71,540 |
28-Mar-2025 | 4,939.15 | 4,980.65 | 4,848 | 4,881.7 | 29,156 | 74,15,69,775.05 | 87,410 |
01-Apr-2025 | 4,889.95 | 4,950 | 4,804.55 | 4,835.55 | 7,934 | 15,95,96,727.15 | 13,083 |
02-Apr-2025 | 4,856.65 | 4,906.25 | 4,788 | 4,887.7 | 11,419 | 36,77,25,566.6 | 41,368 |
03-Apr-2025 | 4,929.95 | 5,012.95 | 4,911.9 | 4,971.55 | 26,666 | 95,72,65,579.9 | 84,252 |
04-Apr-2025 | 4,900 | 4,929.25 | 4,738.55 | 4,828.7 | 15,367 | 40,43,86,791.65 | 36,359 |
07-Apr-2025 | 4,623 | 4,733.95 | 4,611.85 | 4,700.5 | 19,899 | 66,43,68,312.4 | 94,502 |
08-Apr-2025 | 4,799.45 | 4,876.75 | 4,700.65 | 4,837.15 | 17,497 | 38,27,37,813.5 | 41,748 |
09-Apr-2025 | 4,772.15 | 4,852.5 | 4,755.1 | 4,838.85 | 13,663 | 33,38,81,007.35 | 36,240 |
11-Apr-2025 | 4,900 | 4,909.35 | 4,840 | 4,887.45 | 10,561 | 24,85,35,917 | 23,755 |
15-Apr-2025 | 4,900 | 4,950 | 4,852 | 4,920.8 | 14,441 | 47,88,97,144.1 | 45,407 |
16-Apr-2025 | 4,949.9 | 4,985.4 | 4,913.6 | 4,957.6 | 18,599 | 31,78,82,377.6 | 38,853 |
17-Apr-2025 | 4,979 | 4,989.5 | 4,881.1 | 4,953.3 | 9,747 | 22,62,77,780.6 | 22,745 |
21-Apr-2025 | 4,960 | 5,008 | 4,921 | 5,000.4 | 23,958 | 48,69,72,954.9 | 53,761 |
22-Apr-2025 | 5,010 | 5,075 | 4,988.7 | 5,013.6 | 8,974 | 21,69,75,458.1 | 11,751 |
23-Apr-2025 | 5,064.9 | 5,250.5 | 5,020 | 5,233 | 26,320 | 84,21,62,426 | 52,647 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
